pregnancy specific beta-1-glycoprotein 5Genealiases: FL-NCA-3 · PSG
Q-omics provides the consensus-scored PSG5 profile across patient tissues and cancer cell-line models. PSG5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PSG5 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PSG5 RNA expression shows 10,189 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where PSG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSG5 survival associations across molecular data types. PSG5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSG5 RNA expression–survival associations across cancer types. High PSG5 expression shows unfavorable associations in MESO, KIRC, SKCM, LIHC and COAD, but favorable associations in UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PSG5 RNA expression.
This table summarizes PSG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PSG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSG5 shows lower tumor expression in KIRC and KIRP and higher tumor expression in HNSC, THCA, LUAD and KICH. The KIRC box plot shows higher PSG5 RNA expression in normal versus tumor tissue (log2 FC = −0.619, t-test p < 0.001).
This table shows molecular features associated with PSG5 in patient tissues and cancer cell lines. In patient samples, PSG5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
